Sökning: onr:"swepub:oai:DiVA.org:uu-229708" > Higher body weight ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04559naa a2200529 4500 | |
001 | oai:DiVA.org:uu-229708 | |
003 | SwePub | |
008 | 140812s2014 | |||||||||||000 ||eng| | |
009 | oai:lup.lub.lu.se:e97dfbc7-e9ee-4f88-b6b6-b1bd2469f1b4 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2297082 URI |
024 | 7 | a https://doi.org/10.1007/s11239-013-0987-82 DOI |
024 | 7 | a https://lup.lub.lu.se/record/40657092 URI |
040 | a (SwePub)uud (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Wagner, Henriku Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-hkw |
245 | 1 0 | a Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients |
264 | c 2013-09-17 | |
264 | 1 | b Springer Science and Business Media LLC,c 2014 |
338 | a print2 rdacarrier | |
520 | a Body weight is a predictor of clopidogrel response. However, no prospective studies have compared pharmacodynamic (PD) and pharmacokinetic (PK) data based on body weight. We compared PD and PK effects of clopidogrel 75 mg in low body weight (LBW, <60 kg) and higher body weight (HBW, >= 60 kg) patients with stable coronary artery disease. LBW (n = 34, 56.4 +/- 3.7 kg) and HBW (n = 38, 84.7 +/- 14.9 kg) aspirin-treated patients received clopidogrel 75 mg for 10-14 days. The area under the concentration-time curve of active metabolite (Clop-AM) calculated through the last quantifiable concentration up to 4 h postdose, AUC((0-tlast)), was calculated by non-compartmental methods. Light transmission aggregometry (LTA) (maximum platelet aggregation and inhibition of platelet aggregation to 20 mu M adenosine diphosphate (ADP), and residual platelet aggregation to 5 mu M ADP), VerifyNow (R) P2Y12 reaction units (PRU), and vasodilator-associated stimulated phosphoprotein phosphorylation platelet reactivity index (VASP-PRI) were performed. Mean AUC((0-tlast)) was lower in HBW than LBW patients: 12.8 versus 17.9 ng h/mL. HBW patients had higher platelet reactivity as measured by LTA (all p <= 0.01), PRU (207 +/- 68 vs. 152 +/- 57, p < 0.001), and VASP-PRI (56 +/- 18 vs. 39 +/- 17, p < 0.001). More HBW patients exhibited high on-treatment platelet reactivity (HPR) using PRU (35 vs. 9 %) and VASP-PRI (65 vs. 27 %). Body weight correlated with PRU and VASP-PRI (both p < 0.001), and inversely with log transformed AUC((0-tlast)) (p < 0.001). In conclusion, HBW patients had lower levels of Clop-AM, and higher platelet reactivity and rates of HPR than LBW subjects, contributing to their suboptimal response to clopidogrel. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
653 | a Body weight | |
653 | a Clopidogrel | |
653 | a Pharmacodynamics | |
653 | a Pharmacokinetics | |
700 | 1 | a Angiolillo, Dominick J.4 aut |
700 | 1 | a ten Berg, Jurrien M.4 aut |
700 | 1 | a Bergmeijer, Thomas O.4 aut |
700 | 1 | a Jakubowski, Joseph A.4 aut |
700 | 1 | a Small, David S.4 aut |
700 | 1 | a Moser, Brian A.4 aut |
700 | 1 | a Zhou, Chunmei4 aut |
700 | 1 | a Brown, Patricia4 aut |
700 | 1 | a James, Stefanu Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)stjam367 |
700 | 1 | a Winters, Kenneth J.4 aut |
700 | 1 | a Erlinge, Davidu Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)kard-der |
710 | 2 | a Kardiologib Sektion II4 org |
773 | 0 | t Journal of Thrombosis and Thrombolysisd : Springer Science and Business Media LLCg 38:2, s. 127-136q 38:2<127-136x 0929-5305x 1573-742X |
856 | 4 | u http://www.ncbi.nlm.nih.gov/pubmed/24043374?dopt=Abstracty FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1007/s11239-013-0987-8y FULLTEXT |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-229708 |
856 | 4 8 | u https://doi.org/10.1007/s11239-013-0987-8 |
856 | 4 8 | u https://lup.lub.lu.se/record/4065709 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy